Department of Neurosurgery, Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum, Germany.
Acta Neurochir (Wien). 2011 Nov;153(11):2119-25. doi: 10.1007/s00701-011-1129-8. Epub 2011 Aug 21.
Nicardipine prolonged release implants (NPRI) have been shown to decrease the incidence of cerebral vasospasm and infarcts significantly in patients after aneurysmal subarachnoid haemorrhage (SAH) following microsurgical clipping. Yet, the comparison with results after endovascular coiling is lacking. This study was conducted to determine the differences in the incidence of cerebral vasospasm and infarctions between those two treatment modalities
The design of this investigation reflects a case-control study; 27 patients suffering from acute SAH were treated by microsurgical clipping and received an intracisternal implantation of NPRI. Twenty-seven matching consecutive patients after microsurgical treatment without implantation of NPRI or endovascular treatment, respectively, served as controls. The incidence of angiographic vasospasm and cerebral infarctions were documented.
All groups were comparable concerning demographics and severity of SAH. Twenty-four of 81 patients developed angiographic vasospasm (>33% constriction). The incidence of vasospasm was 48%, 44% and 11% for patients after endovascular treatment, microsurgical clipping without NPRI and microsurgical clipping with NPRI, respectively. New cerebral infarctions occurred in 28%, 22% and 7% of the treated patients, respectively. A good clinical recovery 1 year after the initial bleeding (modified Rankin scale 0-2) was seen in 48%, 50% and 77% of the treated patients, respectively.
The use of NPRI during microsurgical clipping was confirmed to be safe and effective. Patients who received intracisternally implanted NPRI during clipping after aneurysmal SAH yielded significantly lower vasospasm and infarction rates, and showed a better clinical outcome when compared with clipping without NPRI and also when compared with endovascular coiling.
尼卡地平缓释植入物(NPRI)已被证明可显著降低显微夹闭术后颅内动脉瘤性蛛网膜下腔出血(SAH)患者的脑血管痉挛和梗死发生率。然而,与血管内治疗的结果比较尚缺乏。本研究旨在确定两种治疗方法在脑血管痉挛和梗死发生率方面的差异。
本研究的设计反映了病例对照研究;27 例急性 SAH 患者接受显微夹闭治疗,并接受了 NPRI 脑室内植入。27 例匹配的连续患者在接受显微治疗但未植入 NPRI 或血管内治疗的情况下作为对照组。记录血管造影血管痉挛和脑梗死的发生率。
所有组在人口统计学和 SAH 严重程度方面均具有可比性。81 例患者中有 24 例出现血管造影性血管痉挛(>33%狭窄)。血管痉挛的发生率分别为血管内治疗患者 48%、显微夹闭无 NPRI 患者 44%和显微夹闭加 NPRI 患者 11%。治疗患者中分别有 28%、22%和 7%出现新的脑梗死。初始出血后 1 年时,48%、50%和 77%的治疗患者获得良好的临床恢复(改良 Rankin 量表 0-2)。
在显微夹闭术中使用 NPRI 被证实是安全有效的。与未植入 NPRI 的夹闭治疗相比,与血管内治疗相比,接受动脉瘤性 SAH 显微夹闭后脑室内植入 NPRI 的患者血管痉挛和梗死发生率显著降低,临床结局更好。